DIA
Drug Information Association Logo

DIA Announces Internationally Acclaimed Leaders as Co-Chairs of Milestone Meeting

WASHINGTON — Nov 06, 2013

Innovators in Industry and Regulation to Chair 50th Annual Meeting 

DIA today announced that two worldwide leaders in the pharmaceutical and medical product development will co-chair the DIA 2014 50th Annual Meeting June 15-19 at the San Diego Convention Center.

Freda C. Lewis-Hall, M.D., chief medical officer and executive vice president of Pfizer Inc., and Rear Adm. (ret) Sandra L. Kweder, M.D., deputy director of the Office of New Drugs for the U.S> Food and Drug Administration’s Center for Drug Evaluation and Research, will bring their renowned expertise to strengthen collaboration and advance therapeutic innovation at the meeting.

“Drs. Kweder and Lewis-Hall have dedicated their careers to advancing science and improving health care,” said Barbara Lopez Kunz, DIA’s global chief executive. “DIA is honored to have two such esteemed and dedicated leaders, who bring both the industry and the regulatory perspective, lending their extensive knowledge and insight to our milestone 50th Annual Meeting.”

Lewis-Hall leads Pfizer Medical, the division devoted to ensuring the safe, effective and appropriate use of every Pfizer product across the world. Prior to joining Pfizer, Lewis-Hall was a leader in medical affairs and biomedical product development with Vertex, Pharmacia, Bristol-Myers Squibb, and Eli Lilly and Company. She also held leadership, clinical, and research positions at the National Institute of Mental Health and the Howard University Hospital and College of Medicine. In 2010, Lewis-Hall was appointed to the inaugural board of governors for the Patient-Centered Outcomes Research Institute (PCORI), which directs a range of research programs to improve the nation’s quality of health care. In 2011, she was named “Woman of the Year” by the Healthcare Businesswomen’s Association. Lewis-Hall received a bachelor’s degree from The Johns Hopkins University and a medical doctorate from the Howard University College of Medicine.

Kweder’s distinguished career has spanned decades in public service and medical advancements. Commissioned into the U.S. Public Health Service in 1980 by the Uniformed Services University of Health Sciences, she completed her residency at the Walter Reed Army Medical Center and fellowship in Obstetric Medicine at Brown University. Her career at FDA began in the Division of Antiviral Drugs to help spearhead the emergent field of HIV drug development. Kweder went on to serve in leadership roles in Postmarketing Surveillance and Epidemiology and the Office of Antimicrobial Products, until she became the deputy director of the Office of New Drugs in 2002. In this position, she oversees the full range of drug and therapeutic biologics, both marketed and in development, as well as special programs such as Pediatrics and Maternal Health, the development of Patient Reported Outcome tools and their qualification as endpoints for clinical trials.

 

Contact: Tiffany Cohen
+1.202.499.4411
tcohen@reingold.com

 

###

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.
 
ABOUT DIA’s 2014 50th ANNUAL MEETING: Celebrate the Past – Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development and life cycle management of medical products. The meeting aims to foster innovation that will lead to the development of safe and effective medical products and therapies for patients. For more information, visit www.diahome.org/dia2014.